SDC4 Marker for Cancer Stem Cell Detection and Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current technologies lack a specific marker molecule that can effectively detect and target cancer stem cells, which are resistant to conventional anticancer therapies and contribute to cancer recurrence and metastasis.

Innovation Solution

The use of Syndecan-4 (SDC4) as a marker molecule for detecting cancer stem cells and as a therapeutic target, where SDC4-specific siRNAs or antibodies are employed to suppress SDC4 expression or function, thereby eliminating cancer stem cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional anticancer agents and radiation therapy are used, then cancer treatment is performed, but cancer stem cells show resistance and cause poor prognosis

Engineering Contradiction:

ImproveprognosisVSAvoidresistance to anticancer agents

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and isolates cancer stem cells from the heterogeneous cancer cell population using specific markers (CD44v9, CD133, ALDH1) and sorting techniques (FACS, flow cytometry). This allows selective targeting of the resistant stem cell subset rather than treating all cancer cells uniformly, thereby overcoming the resistance problem while improving prognosis.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent applies local quality by developing cancer stem cell-specific therapies that target only the stem cell compartment with distinct molecular characteristics. By identifying and treating only the subset of cells with stem cell properties (using markers like CD44v9), the therapy achieves high efficacy against resistant cells while minimizing damage to differentiated cancer cells and normal tissues.

Inventive Principle:

Principle #3Local quality

2Reliability

If cancer stem cells are targeted, then recurrence and metastasis can be prevented, but specific marker molecules for detection are lacking

Engineering Contradiction:

Improvecure rateVSAvoidmarker detection

Core Design Contradiction:

ReliabilityVSDifficulty of detecting and measuring

Solution Approach 1:

The patent uses marker molecules (CD44v9, CD133, ALDH1) as intermediaries to detect and identify cancer stem cells. These markers serve as accessible surrogates that reflect the stem cell state, enabling indirect detection and measurement of cancer stem cells through flow cytometry and other detection methods, thereby solving the detection difficulty while maintaining high cure rates.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Ease of operation

If existing cancer stem cell markers are used, then detection is possible, but the markers are not sufficient for effective targeting and sorting

Engineering Contradiction:

Improvecell sorting efficiencyVSAvoidmarker specificity

Core Design Contradiction:

Ease of operationVSMeasurement precision

Solution Approach 1:

The patent employs multi-functional markers and detection systems that can simultaneously identify, sort, and characterize cancer stem cells. By using a combination of markers (CD44v9, CD133, ALDH1) with different detection capabilities, the system achieves both high specificity for marker identification and efficient cell sorting operations, resolving the contradiction between ease of operation and measurement precision.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250188467A1Cancer stem cell marker and cancer stem cell targeting drug

Publication Date: 2025.06.12 CANCERSTEM TECH INC

AI summary

Provided are a cancer stem cell elimination agent containing a substance that suppresses an expression or function of SDC4, a method for detecting or sorting a cancer stem cell in a cancer cell population, including using an expression of SDC4 as an index, and the like.